Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

16.6%

198 terminated/withdrawn out of 1196 trials

Success Rate

79.0%

-7.5% vs industry average

Late-Stage Pipeline

33%

389 trials in Phase 3/4

Results Transparency

69%

518 of 747 completed trials have results

Key Signals

85 recruiting518 with results162 terminated36 withdrawn

Enrollment Performance

Analytics

Phase 2

335(32.1%)

Phase 3

242(23.2%)

Phase 1

221(21.2%)

Phase 4

147(14.1%)

N/A

95(9.1%)

Early Phase 1

3(0.3%)

1043Total

Phase 2(335)

Phase 3(242)

Phase 1(221)

Phase 4(147)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1196)

Showing 20 of 1196 trials

NCT04994509Phase 3Active Not Recruiting

Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection

Role: lead

NCT06817889Phase 2Recruiting

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

Role: collaborator

NCT07645287Phase 2Recruiting

A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

Role: lead

NCT07178730Phase 3Not Yet Recruiting

NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

Role: collaborator

NCT06374758Phase 4Active Not Recruiting

Accelerated ART Initiation for PWHIV Who Are Out of Care

Role: collaborator

NCT07746999Enrolling By Invitation

North Jersey Community Research Initiative (NJCRI) Study on Transgender Liver Health

Role: collaborator

NCT07601243Phase 1Recruiting

Study of GS-2426 in Participants With Advanced Solid Tumors

Role: lead

NCT06081244Phase 3Recruiting

NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

Role: collaborator

NCT05568095Phase 3Active Not Recruiting

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

Role: collaborator

NCT07683000Phase 3Recruiting

Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

Role: lead

NCT07096193Phase 1Recruiting

Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus

Role: lead

NCT06486441Phase 3Active Not Recruiting

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

Role: lead

NCT05329766Phase 2Active Not Recruiting

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

Role: collaborator

NCT04736173Phase 2Active Not Recruiting

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

Role: collaborator

NCT07527858Phase 2Recruiting

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

Role: lead

NCT07339059Phase 2Recruiting

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Role: collaborator

NCT05814432Phase 3Recruiting

Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS

Role: collaborator

NCT03025308Phase 3Completed

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

Role: collaborator

NCT05840224Phase 1Active Not Recruiting

Study of GS-4528 in Adults With Solid Tumors

Role: lead

NCT05838521Phase 2Recruiting

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Role: collaborator